Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2014

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

Docetaxel 75mg/m2 every 21 days

DRUG

Docetaxel and GM-CSF

Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28

Trial Locations (4)

94115

University of California, San Francisco, San Francisco

97239

Oregon Health and Science University Cancer Institute, Portland

98109

University of Washington, Seattle

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00488982 - Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | Biotech Hunter | Biotech Hunter